Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

v3.21.2
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2021
USD ($)
May 31, 2019
USD ($)
Aug. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Jun. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable, reserve for credit losses                   $ 0  
Accounts receivable                   12,330,000 $ 5,559,000
2019 EMD Serono Supply Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   1,000,000.0 1,000,000.0
BMS Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of programs advancing through preclinical development | Program               4      
Contingent payments   $ 275,000,000.0                  
Deferred revenue                   0 0
2018 BMS Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   1,800,000 1,200,000
2018 Merck Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   5,100,000 18,500,000
Milestone payment receivable upon initiation of IND enabling toxicology study                 $ 15,000,000.0    
Recognition of up front payment                   60,600,000  
Incremental revenue recognized                   9,100,000  
2018 Merck Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Incremental transaction price allocation resulted in additional revenue recognized                   100,000  
Contingent payment received                 15,000,000.0    
2018 Merck Agreement | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   2,500,000  
Number of research programs | Program             3        
Initial transaction price             $ 60,000,000.0        
Upfront payment received                   60,000,000.0  
Constrained variable consideration                   7,500,000  
Milestone payment received                   2,500,000  
Additional milestone payment received                   7,500,000  
Accounts receivable                   2,500,000  
Revenue recognition aggregate contingent payments eligible to receive                   $ 500,000,000  
Milestone Method Revenue Recognition Description                   If one or more products from each of the target programs are developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration  
2018 Merck Agreement | Merck Sharp & Dohme Corp | Accounting Standards Update 2014-09                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total interest of unearned revenue                   $ 7,400,000  
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received       $ 5,000,000.0              
Extended research term       1 year              
Transaction price $ 65,000,000.0     $ 65,000,000.0 $ 60,000,000.0       80,000,000.0    
Constrained variable consideration         $ 5,000,000.0       15,000,000.0    
Revenue reallocated property rights                   9,400,000  
Incremental revenue recognized reallocated target programs                   $ 1,600,000  
Estimated service period                   3 years  
Incremental revenue recognized                   $ 3,200,000  
Adjustments to transaction price                   9,100,000  
Cumulative catch-up in revenue                   14,000,000.0  
2020 Merck Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   0 0
MDA Agreement | EMD Serono                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                   0 $ 0
Contingent payment received           $ 1,500,000     $ 2,000,000.0    
Milestone payment received     $ 1,000,000.0                
Maximum amount eligible to receive for each product developed                   $ 52,500,000